CTLA4 Aptamer
Our developed aptamers are CTLA4 specific that promote anti-tumor immunity by unleashing T cells.
Our CTLA4 aptamers promote the anti-tumor cell activities of CD8+ T cells.
Our CTLA4 aptamers enhance CD8 T cell cytolytic activity to both hypermutated and nonhypermutated tumor cell-lines, HCT 15 and
COLO205, respectively.
CTLA4 aptamer, R2-13, showed significantly enhanced CD8 T cell cytolytic activity.
As compared to the CD8 T cell cytolytic activity of CTLA4 monoclonal antibodies, our CTLA4 aptamers showed enhanced cell lysis activity.
We have 5 CRLA4 aptamers, R2-13, R3-25, R2-81, R3-20, and R3-56 that specifically bind to CTLA4 and NKG2A immune-checkpoint proteins of CTLs and NK cells.
Our aptamers do not bind to PD-1 (immune checkpoint protein on CTLs, Bovine serum albumin (BSA), and D-dimer proteins.
Our aptamers only bind to surface receptors such as CTLA4 and NKG2A expressed on activated T cells and NK cells.
Our CTLA4 aptamers promote the anti-tumor cell activities of CD8+ T cells.
Our CTLA4 aptamers enhance CD8 T cell cytolytic activity to both hypermutated and nonhypermutated tumor cell-lines, HCT 15 and COLO205, respectively.
CTLA4 aptamer, R2-13, showed significantly enhanced CD8 T cell cytolytic activity.
As compared to the CD8 T cell cytolytic activity of CTLA4 monoclonal antibodies, our CTLA4 aptamers showed enhanced cell lysis activity.
